In a study published January 2023 in the journal Vector-Borne and Zoonotic Diseases, the ELISAs were evaluated against esta-blished CE-marked tests using samples from patients with acute-phase infections. There was a strong correlation between results from the EUROIMMUN ELISAs and results from another manufacturer’s ELISAs, whereby the sensitivity of the EUROIMMUN tests was higher for both IgM and IgG. Compared to the reference indirect immunofluorescence test from EUROIMMUN, the EUROIMMUN IgM ELISA showed a 98.0% sensitivity in the acutephase samples. This high sensitivity reinforces results from a 2021 study published in PLOS Neglected Tropical Diseases, in which the EUROIMMUN IgM ELISA showed a sensitivity of 100% in acute and convalescent cases. IgG tests are mainly used for disease monitoring, epidemiological studies and surveillance. In cases of subsided CCHF, the EUROIMMUN IgG ELISA demonstrated a sensitivity of 98.8%, confirming its value for disease surveillance.
The EUROIMMUN Anti-CCHFV IgM and IgG ELISAs are CE marked and can be fully automated on ELISA processors such as the EUROLabWorkstation ELISA or the EUROIMMUN Analyzer I or I-2P.
For more information, visit: www.euroimmun.com
Digital issue: Please click here for more information